News & Videos - ASTRAZENECA PLC

Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity Building on recent findings from the Regeneron Genetics Center, novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities PR Newswire TARRYTOWN, N.Y., July 27, 2021 TARRYTOWN, N.Y. , July 27, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a...

Un vuelo con más de 800 mil vacunas de AstraZeneca llegó hoy al país para reforzar el plan de inmunización gubernamental contra el coronavirus, con lo cual ......

La France a décidé d'envoyer du matériel médical aux hôpitaux tunisiens, dont de l'oxygène. Paris va également apporter plus de 600 000 doses du vaccin ......

AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and Drug Administration (FDA) is the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in this population, supported by the positive results of the BCB114...

Thinking about buying stock in Ardelyx, AstraZeneca, Rocket Companies, Teva Pharmaceutical, or JetBlue Airways? PR Newswire NEW YORK, July 20, 2021 NEW YORK , July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AZN, RKT, TEVA, and JBLU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ARDX:...

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca PR Newswire LOS GATOS, Calif., July 19, 2021 LOS GATOS, Calif. , July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab. The highlights of the agreement are:...

...

"The airlines we spoke to had no idea of what the implications were." Andy Hill tells RT UK how his foreign holiday is in doubt after France, Italy and Croatia ban ......

Thinking about trading options or stock in General Electric, Pinterest, Square, AstraZeneca, or Upstart Holdings? PR Newswire NEW YORK, July 12, 2021 NEW YORK , July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GE, PINS, SQ, AZN, and UPST. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects...

El dibujante Miguel Rep nos cuenta una historia de la que poco se conoce. En “La Historia Dibujada” se refiere a los hermanos Kennedy, tres hacendados ......

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen. The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The...

...

euronews: der meistgesehene Nachrichtensender in Europa. Abonnieren Sie!...

Argentina alcanzó hoy casi 25 millones de vacunas recibidas desde el inicio de la pandemia, con el arribo esta tarde de una nueva partida de 1.181.500 de ......

Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca’s exenatide extended-release 2mg once weekly significantly reduced blood sugar—as measured by HbA1c—versus placebo in adolescents aged 10–17 with type 2 diabetes (T2D). This Phase III trial is the first and only completed trial of a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in adolescents aged 10–17 with T2D. The results were presented today at the 2021 American Diabetes Association...

...

El vuelo que trajo más de un millón de vacunas AstraZeneca contra el coronavirus desarrollada por el laboratorio Astrazeneca y la Universidad de Oxford y ......

...

...

...